Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount

“Caribou’s story has taken a heartbreaking turn,” says CEO Rachel Haurwitz, with the CRISPR-focused biotech set to discontinue vispa-cel and CB-011, and reduce its workforce

October 12, 2026
3 min

The Medicine Maker

Overview

Caribou Biosciences plans to discontinue development of its two allogeneic CAR T-cell candidates and substantially reduce its workforce after failing to secure funding for continued development. The board is reviewing strategic alternatives, including a possible merger, acquisition, business combination, or transaction involving the company or its assets; no timetable has been set.

Background

Allogeneic CAR T-cell therapies use donor-derived cells and are intended to be available off the shelf, unlike autologous products manufactured from a patient's own cells. Developers aim to reduce manufacturing delays and extend access, but clinical evidence generation and late-stage development require substantial investment. Caribou's candidates targeted relapsed or refractory B-cell non-Hodgkin lymphoma and multiple myeloma, respectively. The supplied context notes that FDA-approved CAR T-cell products remain autologous, while allogeneic CAR T therapies remain investigational.

Data Highlights

Item	Source-reported detail
Cash, cash equivalents, and marketable securities	$113.8 million as of June 30
Previously projected cash runway	Expected to support operations until the end of 2027, including CB-011 dose expansion and preparations for a phase III vispa-cel trial
Vispa-cel (formerly CB-010)	Allogeneic anti-CD19 CAR T-cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma; FDA agreement on pivotal phase III trial design
CB-011	Allogeneic anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
Workforce reduction	Expected to be largely completed during the fourth quarter of 2026

Key Findings

Caribou plans to discontinue both allogeneic CAR T programs after struggling to secure the capital needed to advance them.
Vispa-cel, previously called CB-010, is an anti-CD19 candidate incorporating a PD-1 knockout intended to limit premature T-cell exhaustion; Caribou said it was ready to enter a pivotal phase III study.
CB-011 is an anti-BCMA candidate for relapsed or refractory multiple myeloma, using a B2M knockout and insertion of a B2M–HLA-E-peptide fusion protein intended to reduce immune rejection.
Both candidates received FDA Regenerative Medicine Advanced Therapy, Fast Track, and Orphan Drug designations.
Caribou's board has begun a strategic review that may include a merger, acquisition, business combination, or transaction involving the company or its assets; Wedbush Securities is advising, and no completion timetable has been set.
The company reported $113.8 million in cash, cash equivalents, and marketable securities on June 30, and had previously projected that funds would support operations through the end of 2027.

Clinical Implications

Under Caribou's current plans, neither candidate will progress further, although CEO Rachel Haurwitz said she hoped another organization could acquire and continue the programs. The supplied context describes allogeneic CAR T therapies as investigational and notes that FDA-approved CAR T products remain autologous.

Conclusion

Caribou's decision halts its planned development of vispa-cel and CB-011 amid funding constraints, while the board evaluates strategic alternatives. Any continuation of the candidates would depend on a future organizational or asset transaction.